We improve patient outcomes and reduce healthcare costs by suPARcharging triage
Triage suPARcharged
The suPAR biomarker predicts critical illness across diseases by measuring the level of activation in the immune response.
suPARnostic® is a reliable prognostic tool that enables healthcare professionals to make quick and informed patient triaging decisions at emergency departments.
How to interpret suPAR results
suPAR level < 4 ng/mL
Supports patient discharge
suPAR level > 6 ng/mL
Supports patient hospitalisation
Empowering clinical decisions
suPARnostic® empowers healthcare professionals to lead patient triage with confidence by making better-informed decisions backed by reliable biological data across diseases.
Implementing the biomarker suPAR in clinical care delivers faster and safer patient discharges, reduces re-admissions, unnecessary admissions, as well as hospital length-of-stay. – Freeing up critical resources, valuable time, and saving hospital beds for those who need them.
Improve patient care
Up to 22% reduction in hospital admissions and up to 6% reduction in hospital length-of-stay per patient
Reduce healthcare costs
Up to €100-380 savings per admission depending on medical specialty and geography
Empower clinical staff
Get more information to make more confident decisions to potentially reduce uncertainty
“it is essential to have the help of biomarkers, such as suPAR, which can support the discharge decision”
Juan González del Castillo,
Dr PhD, Hospital Clínico San Carlos, Spain
suPAR News Vol. 1, April 2019
How suPARnostic® works at the emergency department
Step 1
A patient is admitted to the emergency department for observation
Step 2
The patient’s blood sample is drawn
Step 3
The patient’s suPAR level is measured at the central lab
(~20 minutes) and fits existing hospital workflow.
Step 4
The physician gets the result and makes a triage decision
suPAR is a significant independent predictor of mortality of emergency department patients
| All | suPAR ≤ 4 ng/mL | suPAR > 4 and < 6 ng/mL | suPAR ≥ 6 ng/ml | P Value | |
|---|---|---|---|---|---|
| N | 1747 | 804 | 514 | 429 | |
| Discharge < 24 H N | 785 | 462 | 215 | 108 | < 0.001 |
| 30 Day pre-admitted N | 379 | 131 | 121 | 127 | < 0.001 |
| Readmission 30 Days N | 368 | 153 | 114 | 101 | 0,14 |
| Mortality 7 Days N | 34 | 3 | 9 | 22 | < 0.001 |
| Mortality 30 Days N | 81 | 6 | 25 | 50 | < 0.001 |
| Mortality 90 Days N | 138 | 8 | 43 | 87 | < 0.001 |
* Santeri, S., Peter, A.A., Kristiina, N. et al. suPAR cut-offs for stratification of low, medium, and high-risk acute medical patients in the emergency department. BMC Emerg Med 21, 149 (2021).
* suPAR values should be used in conjunction with clinical findings and the results of other laboratory parameters. suPAR values alone are not indicative of the need for mechanical ventilation.
1. Soluble urokinase plasminogen activator receptor (suPAR) as an early predictor of severe respiratory failure in patients with COVID-19 pneumonia. Rovina N et al. Crit Care. 2020 4(1):187. (LINK: https://pubmed.ncbi.nlm.nih.gov/32354367/
2. Soluble Urokinase Receptor (SuPAR) in COVID-19-Related AKI. Azam TU et al. J Am Soc Nephrol. 2020 (LINK: https://pubmed.ncbi.nlm.nih.gov/32963090/
3. Soluble Urokinase-Guided Anakinra To Prevent Respiratory Failure In COVID-19: A Single-Arm Trial. Kyriazopoulou E et al. (preprint, link to be provided when available)
4. Soluble Urokinase Plasminogen Activator Receptor: A Biomarker for Predicting Complications and Critical Care Admission of COVID-19 Patients. Chalkias A et al. Mol Diagn Ther. 2020 (5):517-521. (LINK: https://pubmed.ncbi.nlm.nih.gov/32613288/
5. COVID-19 and pneumonia: a role for the uPA/uPAR system. D’Alonzo D et al. Drug Discov Today. 2020 (8):1528-1534. Review. (LINK: https://pubmed.ncbi.nlm.nih.gov/32562843/
